PubMed
Cartilage bioregulatory peptide in osteoarthritis models (preclinical review)
Khavinson et al., 2014
Healing & RecoveryResearch OnlyD
Cartalax
Cartilage Bioregulator
Investigational peptide discussed for cartilage and connective-tissue support.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 3
- Research grade
- D
- Experience
- 81
- Activity
- 63
Overall check-ins
Trackers & reports
Overview
About Cartalax
Investigational peptide discussed for cartilage and connective-tissue support.
- Category
- Healing & Recovery
- Regulatory status
- Research Only
- Also known as
- Cartilage Bioregulator
- Self-reports
- 27
Community
What 27 users report
27 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 57% · Mixed 43% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
180
Self-reported dose per injection
Median bucket: 2+ mg · Most common: 2+ mg
Reports span 2 to ≥ 2 mg (open-ended top bucket)
2+ mg
180
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 88% said they felt similar to their last entry, 13% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 197 days · Based on 24 repeat reporters
Research
Cited research (2)
Source
PubMed
Peptide bioregulation of aging: results and prospects
Khavinson, 2009
Tools
Explore more
Explore
More ways to learn about Cartalax from observational PeptIQ data.
Related peptides
Help
Frequently asked
What do PeptIQ users report about Cartalax?
This page summarizes 27 anonymized self-reports from PeptIQ users who track Cartalax, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for Cartalax?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for Cartalax?
2 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is Cartalax safe to use?
This wiki does not assess safety or recommend use. Cartalax is listed as Research Only. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of Cartalax?
Research, primarily in animal models, suggests Cartalax may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceWhat is the legal status of Cartalax?
Cartalax is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified Cartalax as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceWhat are the known or theoretical side effects and risks of Cartalax?
The safety and effectiveness of Cartalax have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhat is the current state of research on Cartalax?
While there are over 200 published studies on Cartalax, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source